OBJECTIVE: To determine the baseline prevalence of tuberculosis (TB) in a cohort using a strategy of intensive pretreatment screening for TB and the subsequent incidence rate and temporal distribution of cases during the first year of antiretroviral therapy (ART). DESIGN: Prospective observational community-based ART cohort in South Africa. METHODS: Adults enrolling for ART and who did not have a current TB diagnosis were intensively screened for TB at baseline using culture of two sputum samples, chest radiography and investigations for extrapulmonary disease as required. Patients who developed symptoms consistent with incident TB during ART were similarly investigated. RESULTS: Two hundred forty-one patients had a median CD4 cell count of 125 cells/microl (interquartile range 70-186) and 200 (83%) started ART. TB was diagnosed in 87 (36%) patients, with 82% of pulmonary cases being culture-proven. Most TB cases (87%) were prevalent disease detectable at baseline, whereas just 11 (13%) were incident cases that presented during the first year of ART. The incidence rate during 0-4 months of ART was similar to the rate during months 5-12 of ART [10.9 (95% confidence interval [CI] 4.6-23.3) cases per 100 person-years versus 8.1 (95% CI 3.6-18.0) cases per 100 person-years]. CONCLUSION: Systematic culture-based screening detected a very high burden of prevalent TB present at baseline. This intensified screening strategy was associated with an approximately two-fold lower incidence rate in the first 4 months of ART than previously observed in this cohort. This suggests that many incident cases of symptomatic TB presenting during early ART can be detected as prevalent disease prior to ART initiation using sensitive diagnostic tests.
OBJECTIVE: To determine the baseline prevalence of tuberculosis (TB) in a cohort using a strategy of intensive pretreatment screening for TB and the subsequent incidence rate and temporal distribution of cases during the first year of antiretroviral therapy (ART). DESIGN: Prospective observational community-based ART cohort in South Africa. METHODS: Adults enrolling for ART and who did not have a current TB diagnosis were intensively screened for TB at baseline using culture of two sputum samples, chest radiography and investigations for extrapulmonary disease as required. Patients who developed symptoms consistent with incident TB during ART were similarly investigated. RESULTS: Two hundred forty-one patients had a median CD4 cell count of 125 cells/microl (interquartile range 70-186) and 200 (83%) started ART. TB was diagnosed in 87 (36%) patients, with 82% of pulmonary cases being culture-proven. Most TB cases (87%) were prevalent disease detectable at baseline, whereas just 11 (13%) were incident cases that presented during the first year of ART. The incidence rate during 0-4 months of ART was similar to the rate during months 5-12 of ART [10.9 (95% confidence interval [CI] 4.6-23.3) cases per 100 person-years versus 8.1 (95% CI 3.6-18.0) cases per 100 person-years]. CONCLUSION: Systematic culture-based screening detected a very high burden of prevalent TB present at baseline. This intensified screening strategy was associated with an approximately two-fold lower incidence rate in the first 4 months of ART than previously observed in this cohort. This suggests that many incident cases of symptomatic TB presenting during early ART can be detected as prevalent disease prior to ART initiation using sensitive diagnostic tests.
Authors: Maryline M B Bonnet; Loretxu L P Pinoges; Francis F V Varaine; Barbara B O Oberhauser; Daniel D O O'Brien; Yared Y K Kebede; Cathy C H Hewison; Rony R Z Zachariah; Laurent L F Ferradini Journal: AIDS Date: 2006-06-12 Impact factor: 4.177
Authors: F S Rana; M P Hawken; C Mwachari; S M Bhatt; F Abdullah; L W Ng'ang'a; C Power; W A Githui; J D Porter; S B Lucas Journal: J Acquir Immune Defic Syndr Date: 2000-05-01 Impact factor: 3.731
Authors: Neel R Gandhi; Anthony Moll; A Willem Sturm; Robert Pawinski; Thiloshini Govender; Umesh Lalloo; Kimberly Zeller; Jason Andrews; Gerald Friedland Journal: Lancet Date: 2006-11-04 Impact factor: 79.321
Authors: David Moore; Cheryl Liechty; Paul Ekwaru; Willy Were; Gerald Mwima; Peter Solberg; George Rutherford; Jonathan Mermin Journal: AIDS Date: 2007-03-30 Impact factor: 4.177
Authors: S B Lucas; A Hounnou; C Peacock; A Beaumel; G Djomand; J M N'Gbichi; K Yeboue; M Hondé; M Diomande; C Giordano Journal: AIDS Date: 1993-12 Impact factor: 4.177
Authors: Katharina Kranzer; Rein Mgj Houben; Judith R Glynn; Linda-Gail Bekker; Robin Wood; Stephen D Lawn Journal: Lancet Infect Dis Date: 2010-02 Impact factor: 25.071
Authors: Alice A Zwerling; Maitreyi Sahu; Lucky G Ngwira; McEwen Khundi; Tina Harawa; Elizabeth L Corbett; Richard E Chaisson; David W Dowdy Journal: J Acquir Immune Defic Syndr Date: 2015-09-01 Impact factor: 3.731
Authors: Neil A Martinson; Grace L Barnes; Lawrence H Moulton; Reginah Msandiwa; Harry Hausler; Malathi Ram; James A McIntyre; Glenda E Gray; Richard E Chaisson Journal: N Engl J Med Date: 2011-07-07 Impact factor: 91.245
Authors: Paul K Drain; Kristina L Bajema; David Dowdy; Keertan Dheda; Kogieleum Naidoo; Samuel G Schumacher; Shuyi Ma; Erin Meermeier; David M Lewinsohn; David R Sherman Journal: Clin Microbiol Rev Date: 2018-07-18 Impact factor: 26.132
Authors: Julia del Amo; Santiago Moreno; Heiner C Bucher; Hansjakob Furrer; Roger Logan; Jonathan Sterne; Santiago Pérez-Hoyos; Inma Jarrín; Andrew Phillips; Sara Lodi; Ard van Sighem; Wolf de Wolf; Caroline Sabin; Loveleen Bansi; Amy Justice; Joseph Goulet; José M Miró; Elena Ferrer; Laurence Meyer; Rémonie Seng; Giota Toulomi; Panagiotis Gargalianos; Dominique Costagliola; Sophie Abgrall; Miguel A Hernán Journal: Clin Infect Dis Date: 2012-03-28 Impact factor: 9.079